DVA — DaVita Inc.

Summary of DaVita (DVA) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Adjusted Operating Income: $586 million; Full Year: $2.094 billion.
• Adjusted Earnings Per Share (EPS): Q4 at $3.40; Full Year at $10.78.
• Free Cash Flow: $309 million in Q4; over $1 billion for the full year.
• U.S. Dialysis Treatments: Declined by 1.1% for the year; Q4 treatments down 20 basis points year-over-year.
• Revenue Per Treatment (RPT): Increased approximately $12 sequentially in Q4, with a full-year RPT of $410 (up 4.7%).
• Patient Care Cost per Treatment: Increased by approximately $6 sequentially, finishing 5.9% higher than 2024.

2. Strategic Updates and Business Highlights

• Integrated Kidney Care (IKC): Achieved first profitable year ahead of schedule, with a reported operating income of $22 million for the full year. IKC patients showed significantly better clinical outcomes.
• Clinical Initiatives: Focus on vaccination rates, GLP-1 drug adoption, and advanced dialysis technologies to improve patient outcomes and reduce hospitalizations.
• Partnership with Elara Caring: Announced a strategic investment to enhance home care services for kidney disease patients, aimed at reducing hospitalizations and missed treatments.
• International Business: Contributed positively with an adjusted operating income of $114 million, driven by organic growth and acquisitions.

3. Forward Guidance and Outlook

• 2026 Adjusted Operating Income Guidance: Expected between $2.085 billion and $2.235 billion, reflecting 3.2% growth at the midpoint.
• Adjusted EPS Guidance: Projected between $13.60 and $15.00, indicating a 33% growth at the midpoint.
• Free Cash Flow Guidance: Anticipated between $1 billion and $1.25 billion.
• Treatment Volume: Expected to be flat compared to 2025, with a focus on improving clinical outcomes to drive future growth.

4. Challenges and Points of Concern

• Treatment Growth Pressure: Continued challenges from elevated mortality rates and the expiration of enhanced premium tax credits, which could impact revenue.
• Cost Increases: Rising patient care costs and health benefit costs are affecting margins.
• Cyber Incident Impact: Although the financial impact from the cyber incident is expected to lessen, it still poses a lingering concern for operational stability.
• Volume Growth: The company is cautious about achieving its long-term target of 2% volume growth, citing the need for improved mortality rates and treatment adherence.

5. Notable Q&A Insights

• Volume Growth Confidence: CEO Javier Rodriguez emphasized that achieving volume growth hinges on improving clinical outcomes and reducing mortality, with expectations for benefits to materialize over the next few years.
• ACA Headwinds: The company anticipates a $40 million headwind from the expiration of enhanced premium tax credits in 2026, with open enrollment performing better than expected.
• IKC Performance: The outperformance in IKC was attributed to better shared savings and clinical interventions, with expectations for continued growth in operating income.
• Investment in Elara Caring: The investment is both a financial commitment and a strategic move to improve patient care, particularly for home health services.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of DaVita's performance and outlook.